D&D Pharmatech Inc. (KOSDAQ:347850)
South Korea · Delayed Price · Currency is KRW 74,000
+5,300 (7.71%)
Apr 10, 2026, 3:30 PM KST
D&D Pharmatech Revenue
In the year 2025, D&D Pharmatech had annual revenue of 4.30B KRW, down -62.42%. D&D Pharmatech had revenue of 990.09M in the quarter ending December 31, 2025, a decrease of -80.42%.
Revenue
4.30B
Revenue Growth
-62.42%
P/S Ratio
749.63
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.22T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.30B | -7.14B | -62.42% |
| Dec 31, 2024 | 11.44B | -7.24B | -38.77% |
| Dec 31, 2023 | 18.68B | 18.07B | 2,958.97% |
| Dec 31, 2022 | 610.57M | -753.54M | -55.24% |
| Dec 31, 2021 | 1.36B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chabiotech | 1.27T |
| SK Biopharmaceuticals | 706.74B |
| SK bioscience | 651.37B |
| PharmaResearch | 536.29B |
| Hugel | 425.11B |
| LigaChem Biosciences | 141.55B |
| HLB Co., Ltd. | 84.17B |
| OliX Pharmaceuticals | 14.67B |